EUSA Wins U.S. Approval of Erwinaze; Shipping To Start Week Of Nov. 20
This article was originally published in The Pink Sheet Daily
Executive Summary
Eusa hopes the approval will help cement its efforts in the U.S., where it has been trying to build a strong presence for several years.
You may also be interested in...
Jazz Enters Oncology Market With EUSA Acquisition
Jazz strays away from its CNS focus with a $700 million acquisition of EUSA Pharma, adding the specialty pharma’s oncology product to its portfolio.
With U.S Approval, EUSA Set To Prove Value of Transatlantic Spec Pharma Model – And Orphan Focus
U.S approval of orphan drug Erwinase puts specialty pharma firm EUSA on new growth trajectory, showing the value of its strategy to build a transatlantic infrastructure for niche products – and transitioning it from a commercially-focused to a development-capable organization.
Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
The National Organization for Rare Disorders’ campaign to get FDA to codify a flexible approach on approving orphan drugs is now bolstered by an analysis that concludes most of the agency’s approval decisions for such products already use unconventional efficacy standards.